CAR-T – Leukaemia Care e-learning

CAR T-cell therapy involves modifying the T-cells in the body so that they attack the leukaemia cells more efficiently.
Tisagenlecleucel is a CAR T-cell therapy developed to identify and eliminate leukaemia cells which have the CD19 protein. It is the first approved CAR T‑cell for the treatment of ALL.
Tisagenlecleucel is recommended for the treatment of patients with relapsed or refractory B-cell ALL in people aged up to 25 years.